mupirocin and chlorhexidine
ApprovedSmall molecule
mupirocin and chlorhexidine is one of 2 small molecule programs targeting Staphylococcus Aureus. It is currently in Approved.
1
Indications
3
Total Trials
0
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Staphylococcus Aureus
#DrugCompanyPhaseTrials
1mupirocin and chlorhexidine
JJohns Hopkins University
Approved
AZD7760
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Staphylococcus Aureus2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mupirocin and chlorhexidine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- JJohns Hopkins University